Skaarup SH, Schmid JM, Skjold T, et al. - Researchers determined the impact of intralymphatic Allergen ImmunoTherapy (AIT) [ILIT] in this three-year follow-up double-blinded randomized placebo-controlled trial. Overall 36 patients with grass pollen rhinoconjunctivitis participated. The patients were manged with either three ILIT injections and an ILIT booster one year later, three ILIT injection and a placebo booster or three placebo injections and a placebo booster. Improvement in a combined symptom and medication score was the primary outcome. Findings revealed that intralymphatic immune therapy afforded a substantial decrease in grass pollen allergy symptoms as well as use of rescue medication, significant in the first season post-treatment. No additional impact of a booster injection was evident.